LONDON, Nov 6 (Reuters) - Novo Nordisk is

aware of 100 hospitalizations and 10 deaths resulting from

people taking compounded copies of its popular weight-loss and

diabetes drugs, the drugmaker's finance chief said on Wednesday.

Chief Financial Officer Karsten Munk Knudsen told a media

briefing after the company released third-quarter results that

the company had been looking at "a number of compounded products

in the market and identified multiple safety concerns" as well

as the reports of hospitalizations and deaths.

(Reporting by Maggie Fick; Editing by Jan Harvey and Emelia

Sithole-Matarise)